biotech · Sleep · T-Cell Acute Lymphoblastic Leukemia/Lymphoma · BEAM
Beam Therapeutics
Beam Therapeutics clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2017
- Employees
- 573
- Programs
- 10
- Drugs
- 14
- Patents
- 14
Beam Therapeutics projects
10 ClinicalTrials.gov programs sponsored by Beam Therapeutics.
Beam Therapeutics has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BEAM-101
Beam Therapeutics
Sickle Cell Disease
1 trial -
BEAM-201
Beam Therapeutics
Lymphoblastic Lymphoma
1 trial -
BEAM-301: Single dose of BEAM-301 administered by IV
Beam Therapeutics
Glycogen Storage Disease Type Ia
1 trial -
BEAM-302
Beam Therapeutics
Alpha 1-Antitrypsin Deficiency
1 trial -
BEAM-302
Beam Therapeutics
Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease
1 trial -
Allogeneic anti-CD7 CAR-T cells (BEAM-201)
Beam Therapeutics
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
1 trial -
BEAM-103
Beam Therapeutics
Healthy Subjects
1 trial -
BEAM Dream Powder
Beam Therapeutics
Sleep
1 trial -
Beam Organics Dream Powder
Beam Therapeutics
Sleep
1 trial -
PRDR
Beam Therapeutics
Glioma
1 trial
Frequently asked questions
How many clinical projects does Beam Therapeutics have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.